SIM
EGRX

Spark Investment Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Spark Investment Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-23,900
Closed -$962K – 736
2018
Q4 		$962K Buy
+23,900
New +$1.23M 0.07% 324
2018
Q1 		– Sell
-24,200
Closed -$1.29M – 751
2017
Q4 		$1.29M Buy
+24,200
New +$1.35M 0.07% 337
2015
Q3 		– Sell
-7,300
Closed -$590K – 762
2015
Q2 		$590K Buy
+7,300
New +$476K 0.08% 325

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Spark Investment Management's EGRX Position: Q1 2019 in Review

Spark Investment Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2019, closing a stake of 23,900 shares — an estimated $962K sold.

Spark Investment Management first reported a position in EGRX in Q2 2015 and held it in 3 quarters. The position peaked at $1.29M in Q4 2017. 182 funds tracked by Wall St. Rank hold EGRX as of Q1 2019.

  • Spark Investment Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Spark Investment Management sold 23,900 Eagle Pharmaceuticals, Inc. shares in Q1 2019, an estimated $962K.
  • Spark Investment Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 3 quarters.
  • Spark Investment Management's Eagle Pharmaceuticals, Inc. position peaked at $1.29M in Q4 2017.
  • 182 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2019.

Based on Spark Investment Management's 13F filing for Q1 2019, filed 7 May 2019.